Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric herpes zoster subunit vaccine study in immunocompromised renal transplant recipients
2022-502784-37-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Sep 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of Zoster vaccine recombinant in herpes zoster (HZ) (2 arms), sponsored by GSK. Primary endpoints: Solicited local and general adverse events by age category, Unsolicited adverse events by age category and 4 more. Planned start Sep 2019; status: authorised.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2022-502784-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502784-37-00.